Immutrin in a £65M series A led by Frazier Life Sciences, joined by SR One, Qiming Venture Partners, Cambridge Enterprise Ventures and F-Prime
07 March 2026
07 March 2026
Total investments received (USD): 88.33M
Round value (USD): 88.33M
Company: Immutrin
Related deals
R1 Therapeutics secured a $77.5 million Series A led by Abingworth, F-Prime Capital and DaVita Venture Group.
Investments
01 March 2026
Chemify in a $50 million equity deal series B Extension backed by Zeon ventures from Japan
Investments
14 February 2026
Tenpoint Therapeutics raises $85M series B with Janus Henderson Investors, Hillhouse Investment, EQT and British Business Bank
Investments
30 January 2026
Beacon Tx raised $75m in Series C led by Goldman Sachs Alternatives, joined by the RD Fund, Syncona, Forbion, Oxford Science Enterprises, and Advent.
Investments
29 December 2025
Bit.bio raised $50m in Series C funding round led by M&G Investments.
Investments
29 December 2025
Belgium
Austria
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Ireland
Italy
Portugal
Spain